Trial Profile
A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 3076226 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Lymphoma; Malignant melanoma; Multiple myeloma; Oesophageal cancer; Ovarian cancer; Rectal cancer; Renal cancer; Salivary gland cancer; Small cell lung cancer; Soft tissue sarcoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 15 Jul 2021 Results published in the Investigational New Drugs
- 11 Jun 2018 Status changed from active, no longer recruiting to completed.
- 23 Apr 2018 Status changed from recruiting to active, no longer recruiting.